The major function of the Administrative Core is to provide an organizational structure through which the investigators can interact and communicate with each other to foster the fundamental goal of the SPORE, i.e., translation of basic biologic information to and from the clinic in order to improve the survival and quality of life for patients with lymphoma. This core will function via several standing committees of the SPORE including the Steering Committee, the Committee of Program and Core Leaders, the Developmental Research Program Review Committee, the Career Development Program Committee, the Institutional Advisory Committee, and External Advisory Board. These committees consist of the senior leadership of the SPORE and the Universities of Rochester and Arizona, as well as national lymphoma experts and lay advocates. The Administrative Core of the Lymphoma SPORE is the central administrative organization responsible for managing all aspects of the SPORE grant including communication with and reporting to the NCI, communication with other Lymphoma SPOREs, grant accounting and reconciliation, submission of grant related publications, etc. Dr. Richard Fisher will serve as Director of the Administrative Core, and Dr. Thomas Miller as Co-Director. Dr.'s Fisher and Miller will work collaboratively to provide expertise in translational and clinical lymphoma research. They have extensive administrative experience and are well qualified to provide leadership and direction for the Lymphoma SPORE. The Administrative Core schedules and coordinates all internal and external meetings (tabulated at the end of this section) including travel to the annual NCI SPORE meeting, creates and circulates minutes for those meetings, and coordinates the travel for all investigators and consultants. The administrative core will also establish a web site to facilitate the dissemination of information and to encourage collaborations with other investigators. The web site will be developed as part of the ongoing James P. Wilmot Cancer Center web site, and will be a key mechanism of communication between the University of Arizona and the University of Rochester. Other mechanisms of communication between these two centers, including regular conference calls, meetings, and videoconferences will be arranged by the administrative core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA130805-02
Application #
7905993
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
2
Fiscal Year
2009
Total Cost
$281,130
Indirect Cost
Name
University of Rochester
Department
Type
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Runckel, Kyle; Barth, Matthew J; Mavis, Cory et al. (2018) The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma. Blood Adv 2:3516-3525
Holkova, Beata; Kmieciak, Maciej; Bose, Prithviraj et al. (2016) Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. Leuk Lymphoma 57:635-43
Nedelkovska, Hristina; Rosenberg, Alexander F; Hilchey, Shannon P et al. (2016) Follicular Lymphoma Tregs Have a Distinct Transcription Profile Impacting Their Migration and Retention in the Malignant Lymph Node. PLoS One 11:e0155347
Holkova, Beata; Zingone, Adriana; Kmieciak, Maciej et al. (2016) A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res 22:1067-75
Akhenblit, Paul J; Hanke, Neale T; Gill, Alexander et al. (2016) Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI. Mol Imaging 15:
Havas, Aaron P; Rodrigues, Kameron B; Bhakta, Anvi et al. (2016) Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma. Cancer Biol Ther 17:1240-1252
Zhou, L; Zhang, Y; Chen, S et al. (2015) A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia 29:807-18
Jaramillo, Melba C; Briehl, Margaret M; Batinic-Haberle, Ines et al. (2015) Manganese (III) meso-tetrakis N-ethylpyridinium-2-yl porphyrin acts as a pro-oxidant to inhibit electron transport chain proteins, modulate bioenergetics, and enhance the response to chemotherapy in lymphoma cells. Free Radic Biol Med 83:89-100
Chen, Liu Qi; Howison, Christine M; Spier, Catherine et al. (2015) Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models. Leuk Lymphoma 56:1432-9
Kiebala, Michelle; Skalska, Jolanta; Casulo, Carla et al. (2015) Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach. Exp Hematol 43:89-99

Showing the most recent 10 out of 115 publications